Specific diagnostic value of systemic immune–inflammation indices combined with nutritional and tumor markers in the stage diagnosis of pancreatic cancer: a retrospective cohort study - Scorecard - MDSpire
Advertisement
Specific diagnostic value of systemic immune–inflammation indices combined with nutritional and tumor markers in the stage diagnosis of pancreatic cancer: a retrospective cohort study
Clinical Scorecard: Evaluating the Diagnostic Significance of Combined Systemic Immune-Inflammation Indices and Nutritional and Tumor Markers for Staging Pancreatic Cancer: A Retrospective Cohort Analysis
At a Glance
Category
Detail
Condition
Pancreatic Cancer
Key Mechanisms
Systemic immune–inflammation index (SII), systemic inflammation response index (SIRI), prognostic nutritional index (PNI), tumor markers (CA19-9, CEA)
Target Population
Patients with pathologically confirmed pancreatic cancer
Care Setting
Single-center retrospective cohort study
Key Highlights
SII, SIRI, CA19-9, and CEA levels are higher in non-early-stage pancreatic cancer compared to early-stage.
PNI shows the best diagnostic performance for early-stage pancreatic cancer (AUC = 0.78).
Combined model of SII, SIRI, and PNI achieves an AUC of 0.82, superior to any single marker.
In CA19-9–negative patients, the combined model still demonstrates good diagnostic value (AUC = 0.85).
The study emphasizes the need for multi-marker strategies in diagnosing early-stage pancreatic cancer.
Guideline-Based Recommendations
Diagnosis
Utilize SII, SIRI, PNI, CA19-9, and CEA for comprehensive stage diagnosis of pancreatic cancer.
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
257 patients with pathologically confirmed pancreatic cancer
The study highlights the importance of inflammatory and nutritional markers in diagnosis.
Clinical Best Practices
Incorporate multi-marker strategies for improved diagnostic accuracy in pancreatic cancer.
Consider the use of SII, SIRI, and PNI in conjunction with traditional tumor markers.
